- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04683562
Netrin-1 and Placenta Accreta
August 19, 2022 updated by: Mohammed Khairy Ali, Assiut University
The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta
Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor.
It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta.
Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types.
Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog).
Its receptors have been linked to the processes of apoptosis and angiogenesis.
In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis.
In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells.
Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer.
Serum Netrin-1 levels were high in preeclamptic patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Assiut, Egypt, 71111
- Woman's Health Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age between 20-40 years.
- Singleton pregnancy.
- Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping
Exclusion Criteria:
- Multiple pregnancy,
- Fetal anomalies,
- Preterm premature rupture of membranes, or infection
- Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes
- Patients with known bleeding disorders or on anticoagulant therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Normal pregnancy group
|
Pregnant women at gestational age 28-32 weeks
women delivered at term
|
|
OTHER: Placenta accreta group
|
Pregnant women at gestational age 28-32 weeks
women delivered at term
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Placental Netrin-1 level
Time Frame: 4 weeks
|
will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2021
Primary Completion (ACTUAL)
June 1, 2022
Study Completion (ACTUAL)
June 1, 2022
Study Registration Dates
First Submitted
December 21, 2020
First Submitted That Met QC Criteria
December 21, 2020
First Posted (ACTUAL)
December 24, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 19, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA-NT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.